CHICAGO--(BUSINESS WIRE)--Celsis International plc today announces that GlaxoSmithKline’s New Drug Application (NDA) for Veramyst nasal spray, is the first approval of an NDA that references Celsis’ Rapid Microbiological Method (RMM) as part of a regulatory submission. GlaxoSmithKline uses Celsis’ Rapid Detection systems, an alternative testing method based on ATP Bioluminescence technology, to screen products for microbiological contamination.
